Revenue
No reported data
OKYO Pharma Ltd (OKYO)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
Free cash flow
2021
2022
2023
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Research & development | $8.2M | $6.3M | $1.6M | $348,347 | $518,098 |
| Operating expenses | $7.5M | $6.8M | $4.6M | $3.0M | $1.0M |
| Net income | −$16.8M | −$13.3M | −$5.4M | −$3.4M | −$1.5M |
| Basic EPSper diluted share | -$0.57 | -$0.61 | -$0.36 | -$0.32 | — |
| Diluted EPSper diluted share | -$0.57 | -$0.61 | -$0.36 | -$0.32 | — |